Current status of molecular targeted therapies in hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Suh, S.J. | - |
dc.contributor.author | Yim, H.J. | - |
dc.date.accessioned | 2021-09-06T09:41:17Z | - |
dc.date.available | 2021-09-06T09:41:17Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1598-9992 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/105863 | - |
dc.description.abstract | Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death in Korea. Curative treatment is only possible when the disease is diagnosed at the early stage. The prognosis of patients with HCC is even dismal in advanced stages. No systemic cytotoxic chemotherapy has proven to be beneficial in overall survival. Recently, the understanding of the molecular pathogenesis led to the development of new therapies. With the evidence of dysregulation of critical genes associated with cellular proliferation, growth factor signaling, cell cycling, apoptosis, and angiogenesis in HCC, a number of molecular target agents are under clinical trials. Sorafenib is the first systemic anticancer drug which has proven to gain survival benefit in the global as well as Asia-Pacific trials. However, the survival gain is still modest, and further efforts to improve outcomes in patients with HCC are necessary by developing novel drugs or combining other forms of therapies. This article will review signaling pathways in HCC and introduce molecular target agents under investigation currently. | - |
dc.language | Korean | - |
dc.language.iso | ko | - |
dc.subject | antineoplastic agent | - |
dc.subject | carbanilamide derivative | - |
dc.subject | mitogen activated protein kinase kinase | - |
dc.subject | nicotinamide | - |
dc.subject | protein kinase B | - |
dc.subject | protein kinase inhibitor | - |
dc.subject | somatomedin C receptor | - |
dc.subject | sorafenib | - |
dc.subject | target of rapamycin kinase | - |
dc.subject | Wnt protein | - |
dc.subject | analogs and derivatives | - |
dc.subject | antagonists and inhibitors | - |
dc.subject | Carcinoma, Hepatocellular | - |
dc.subject | human | - |
dc.subject | Liver Neoplasms | - |
dc.subject | metabolism | - |
dc.subject | molecularly targeted therapy | - |
dc.subject | pathology | - |
dc.subject | signal transduction | - |
dc.subject | Antineoplastic Agents | - |
dc.subject | Carcinoma, Hepatocellular | - |
dc.subject | Humans | - |
dc.subject | Liver Neoplasms | - |
dc.subject | Mitogen-Activated Protein Kinase Kinases | - |
dc.subject | Molecular Targeted Therapy | - |
dc.subject | Niacinamide | - |
dc.subject | Phenylurea Compounds | - |
dc.subject | Protein Kinase Inhibitors | - |
dc.subject | Proto-Oncogene Proteins c-akt | - |
dc.subject | Receptor, IGF Type 1 | - |
dc.subject | Signal Transduction | - |
dc.subject | TOR Serine-Threonine Kinases | - |
dc.subject | Wnt Proteins | - |
dc.title | Current status of molecular targeted therapies in hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yim, H.J. | - |
dc.identifier.doi | 10.4166/kjg.2013.61.3.136 | - |
dc.identifier.scopusid | 2-s2.0-84884342570 | - |
dc.identifier.bibliographicCitation | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, v.61, no.3, pp.136 - 146 | - |
dc.relation.isPartOf | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | - |
dc.citation.title | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | - |
dc.citation.volume | 61 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 136 | - |
dc.citation.endPage | 146 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART001752405 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | antineoplastic agent | - |
dc.subject.keywordPlus | carbanilamide derivative | - |
dc.subject.keywordPlus | mitogen activated protein kinase kinase | - |
dc.subject.keywordPlus | nicotinamide | - |
dc.subject.keywordPlus | protein kinase B | - |
dc.subject.keywordPlus | protein kinase inhibitor | - |
dc.subject.keywordPlus | somatomedin C receptor | - |
dc.subject.keywordPlus | sorafenib | - |
dc.subject.keywordPlus | target of rapamycin kinase | - |
dc.subject.keywordPlus | Wnt protein | - |
dc.subject.keywordPlus | analogs and derivatives | - |
dc.subject.keywordPlus | antagonists and inhibitors | - |
dc.subject.keywordPlus | Carcinoma, Hepatocellular | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | Liver Neoplasms | - |
dc.subject.keywordPlus | metabolism | - |
dc.subject.keywordPlus | molecularly targeted therapy | - |
dc.subject.keywordPlus | pathology | - |
dc.subject.keywordPlus | signal transduction | - |
dc.subject.keywordPlus | Antineoplastic Agents | - |
dc.subject.keywordPlus | Carcinoma, Hepatocellular | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Liver Neoplasms | - |
dc.subject.keywordPlus | Mitogen-Activated Protein Kinase Kinases | - |
dc.subject.keywordPlus | Molecular Targeted Therapy | - |
dc.subject.keywordPlus | Niacinamide | - |
dc.subject.keywordPlus | Phenylurea Compounds | - |
dc.subject.keywordPlus | Protein Kinase Inhibitors | - |
dc.subject.keywordPlus | Proto-Oncogene Proteins c-akt | - |
dc.subject.keywordPlus | Receptor, IGF Type 1 | - |
dc.subject.keywordPlus | Signal Transduction | - |
dc.subject.keywordPlus | TOR Serine-Threonine Kinases | - |
dc.subject.keywordPlus | Wnt Proteins | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Pathogenesis | - |
dc.subject.keywordAuthor | Signaling pathway | - |
dc.subject.keywordAuthor | Molecular targeted therapy | - |
dc.subject.keywordAuthor | Sorafenib | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.